Our team executed well in a dynamic environment, leveraging the Danaher Business System to accelerate innovation, drive productivity gains, and deliver better than expected adjusted EPS growth. While we have limited direct revenue or supply chain exposure to the region, we're mindful of potential pressures from a sustained conflict. With the strength of our balance sheet and robust free cash flow generation, we're well positioned for further capital deployment going forward. Sales were $6 billion in the first quarter, and core revenue was up 0.5% year-over-year, with a 2.5% headwind from respiratory revenue partially offsetting 3% core revenue growth in the rest of the business.
Geographically, core revenue in developed markets were down slightly, with a mid-single-digit decline in North America and a mid-single-digit increase in Western Europe. High growth markets were up low single digits with solid performance across most regions, including mid-single digit growth in China. In China, better than expected growth in biotechnology and life sciences more than offset the expected high single-digit decline in diagnostics, which continued to be impacted by volume-based procurement and reimbursement policy changes. Adjusted diluted net earnings per common share of $2.06 were up 9.5% year-over-year.
We generated $1.1 billion of free cash flow in the quarter, resulting in a free cash flow to net income conversion ratio of 105%. Turning to capital deployment, in February, we announced our intention to acquire Masimo, a leading provider of mission critical pulse oximetry and patient monitoring solutions in acute care settings. Now alongside M&A, we made significant progress on organic growth initiatives across Danaher, including new product introductions and strategic partnerships. This closes a historical gap in Beckman's immunoassay test menu and positions Beckman to accelerate new placements, customer wins, and growth as the DxI 9000 rollout continues.
| Metric | Period | Current guidance |
|---|---|---|
| Full-year core revenue growth | FY2026 | low single digit first half, accelerating to mid-single digits exiting Q4 (Reaffirmed) |
| Core revenue growth | Q2 2026 | Sequential improvement from Q1; low single digits in first half (New) |
| First-half earnings growth | H1 2026 | Mid- to high single-digit earnings growth (New) |
| Bioprocessing equipment revenue | FY2026 | Assumes flat on equipment (Improved) |
| China diagnostics VBP headwind | FY2026 | $75 million to $100 million headwind (Validated) |
| Masimo accretion / ROIC | Post-acquisition | Accretive to adjusted EPS in first full year; high single-digit ROIC by year five (Reaffirmed) |
| Metric | YoY | Note |
|---|---|---|
| Total core revenue | +0.5% | 2.5% respiratory headwind partially offset 3% core growth in the rest of the business. |
| Biotechnology segment core revenue | +7% | Bioprocessing grew high single digits on robust commercial therapy demand and China strength, while discovery and medical declined low single digits. |
| Bioprocessing equipment orders | >+30% | First positive year-over-year orders growth in nearly two years off a lighter comp, supported by capacity under-investment and reshoring dynamics. |
| Adjusted operating profit margin | +60 bps to 30.2% | Year-over-year cost savings more than offset the negative impact of lower respiratory revenue. |
| Adjusted diluted EPS | +9.5% to $2.06 | Cost savings and portfolio resilience drove growth despite softer respiratory revenue. |
| China core revenue | +mid-single digits | Better than expected biotechnology and life sciences growth more than offset the expected high single-digit diagnostics decline from VBP. |
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| Bioprocessing equipment order recovery | down double digits prior year | Over 30% year-over-year order growth; guide assumes flat equipment | Rising |
| China recovery | — | Mid-single-digit core growth, double-digit bioprocessing, life sciences reinvesting; diagnostics still pressured by VBP | Rising |
| Respiratory normalization at Cepheid | — | Lighter than normal Q1 season; expects return to ~$1.8 billion endemic run rate | Declining |
| Masimo acquisition | announced February | Process progressing well; expected to close later this year with cost and revenue synergies | Rising |
| AI as a growth and productivity driver | — | Viewed as a tailwind via autonomous science demand and AI-enabled DBS efficiencies | Rising |
| Life sciences stabilization | — | Broad stabilization with pockets of improvement; consumables expected to turn slightly positive for the full year | Rising |